Betamethasone Dipropionate Spray (Sernivo)
Customize your policy alerts
Sign up for meridian Policy MDN.CP.PMN.182 alerts
Get alerted when Policy MDN.CP.PMN.182 changes without checking for updates manually.
Monitor payer policy activity
Policy governing medical necessity criteria, prior authorization, and coverage conditions for betamethasone dipropionate 0.05% spray (Sernivo) for Meridian Health Plan Medicaid members.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial Therapy — Plaque Psoriasis
Covered when ALL of the following are met:
Initial Therapy — Other Indications
If the request is for other diagnoses/indications (must meet 1 or 2):
Continued Therapy — Plaque Psoriasis
Continued therapy covered when ALL of the following are met:
Dosing/Administration
Dosing and administration
Avoid use on face, scalp, axilla, groin, or other intertriginous areas.
Non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider submits sufficient documentation of efficacy and safety in accordance with the Health Plan's off‑label use policy (CP.PMN.53).
Avoid use of the spray on sensitive or intertriginous sites. Per product labeling, do not apply to the face, scalp, axilla, groin, or other intertriginous areas.
Coding and Quantity Limits
Provider Actions and Prior Authorization
Prior authorization required; approvals tied to policy criteria
Prior authorization is required for betamethasone dipropionate 0.05% spray (Sernivo). Approval is granted when the applicable initial or continued therapy criteria in this policy are met. Initial approvals are for one month; continued therapy approvals are up to one month (a single continuous course of therapy up to 4 weeks is recommended).
- Initial approval duration: One month
- Continued therapy approval: Up to one month (single continuous course up to 4 weeks recommended)
Follow Health Plan prior authorization procedures (P&T-reviewed policy)
This policy and its criteria were developed and reviewed by the P&T committee. Providers must follow the Health Plan's standard prior authorization procedures when requesting coverage for this product.
- Policy text documents P&T review and creation of criteria
- Submit requests using the Health Plan's prior authorization process
Required prior topical therapies (step therapy)
Before authorization, the member must have trialed and failed a medium- to ultra‑high‑potency topical corticosteroid (see Appendix B) and trialed and failed calcipotriene, unless contraindicated or clinically significant adverse effects occurred.
- Failure of a medium to ultra‑high potency topical corticosteroid (Appendix B) required unless contraindicated or intolerant
- Failure of calcipotriene required unless contraindicated or intolerant
Step therapy specifics not provided
No additional step therapy details beyond the required trials of topical corticosteroid and calcipotriene are provided in this document fragment.
Submit supportive clinical documentation
Submit supporting clinical documentation with the prior authorization request to demonstrate the member meets all approval criteria.
- Examples: office chart notes, relevant lab results, or other clinical information
Documentation to include P&T history and prescribing information
Include records that document the P&T approval/review history and relevant prescribing information when providing supporting documentation for the request.
- P&T approval and review history documenting creation/updates to criteria
- Prescribing information reference when documenting use
Omitting required documentation may lead to denial
Failure to submit the required supporting documentation (e.g., office notes, lab results, or other clinical information) may result in denial of the prior authorization request.
Use outside recommended sites or dosing can trigger denial
Requests for use outside the label‑recommended anatomic sites or dosing regimen may trigger review or denial; labeling recommends applying the spray topically to affected areas twice daily for up to 4 weeks and avoiding use on the face, scalp, axilla, groin, or other intertriginous areas.
- Recommended regimen: apply topically to affected areas BID for up to 4 weeks
- Avoid use on face, scalp, axilla, groin, or other intertriginous areas
Background
Betamethasone dipropionate topical spray, 0.05% (Sernivo) is a topical corticosteroid formulation marketed for dermatologic use. The FDA‑approved dosing regimen is to apply the spray topically to affected areas twice daily (BID) for up to 4 weeks. The label also advises avoiding application to the face, scalp, axilla, groin, or other intertriginous areas.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.